- Home - Curis, Inc
At Curis, we are developing differentiated therapeutics with the goal of improving the lives of cancer patients Our new animation shows how Emavusertib (CA-4948) is being developed to target hematologic malignancies and other cancers
- Emavusertib (CA-4948) - Curis, Inc
As part of the collaboration with Aurigene, in October 2015, Curis exclusively licensed a program of orally-available, small molecule inhibitors of IRAK4 kinase, including emavusertib (CA-4948)
- Pipeline Overview - Curis, Inc
We are focused on the development and commercialization of innovative therapeutics for the treatment of cancer * IP licensed from Aurigene ** IP licensed to Aurigene *** IP licensed to Genentech Indicates a program included in the Curis intellectual property portfolio, but not currently designated as a priority for clinical development
- Company Overview - Curis, Inc
At Curis, we apply this meaning to cancer, by developing novel therapies for slowing or preventing the progression of cancer and prolonging life – or closing and curi͒ng cancer
- About - Curis, Inc
We are a biotechnology company focused on the development of first-in-class and innovative therapeutics for the treatment of cancer Our clinical stage drug candidates are:
- Management - Curis, Inc
Maureen E Lane, Ph D » Vice President, Clinical and Translational Science
- Curis Corporate Presentation - Curis, Inc
Curis Corporate Presentation highlights the company's innovative cancer therapeutics, clinical-stage drug candidates, and commitment to advancing oncology treatments
- Open Positions - Curis, Inc
We are seeking dedicated, driven, humble, hands-on professionals, from diverse backgrounds, who are passionate about making a difference in the lives of patients and families touched by cancer, and who want to have some fun while doing it
|